Transgene, AstraZeneca in exclusive license option deal for new oncolytic immunotherapies
Transgeen in agreement with AstraZeneca to co-developfive armed oncolytic vaccinia virus candidates. Innovative oncolyticviruses resulting from this collaboration will use Transgene’sproprietary next generation viral platform Invir.IO